A good manufacturing practice method to ex vivo expand natural killer cells for clinical use

Blood Transfusion

Volumn 13, Issue 3, 2015, Pages 464-471

  Torelli, Giovanni F ^a   Rozera, Carmela ^b   Santodonato, Laura ^b   Peragine, Nadia ^a   D'Agostino, Giuseppina ^b   Montefiore, Enrica ^b   Napolitano, Maria R ^b   Monque, Domenica M ^b   Carlei, Davide ^b   Mariglia, Paola ^a   Pauselli, Simona ^a   Gozzer, Maria ^c   Bafti, Mahnaz Shafii ^c   Girelli, Gabriella ^c   Guarini, Anna ^a   Belardelli, Filippo ^b   Foà, Robin ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Anti cancer activity; GMP expansion and activation; Immunotherapy; NK cells

Indexed keywords

CD3 ANTIGEN; CD56 ANTIGEN; INTERLEUKIN 15; INTERLEUKIN 2; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1;

ARTICLE; BLOOD AUTOTRANSFUSION; CANCER CELL LINE; CELL EXPANSION; CRYOPRESERVATION; CYTOLYSIS; CYTOTOXICITY; DEGRANULATION ASSAY; EFFECTOR CELL; EX VIVO STUDY; FEEDER CELL; FLOW CYTOMETRY; GOOD MANUFACTURING PRACTICE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNOFLUORESCENCE; LEUKAPHERESIS; NATURAL KILLER CELL; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; THAWING; UPREGULATION; CELL CULTURE TECHNIQUE; CLINICAL TRIAL; CYTOLOGY; DEVICES; FEMALE; MALE; PROCEDURES; TRANSPLANTATION;

CELL CULTURE TECHNIQUES; CRYOPRESERVATION; FEMALE; HUMANS; KILLER CELLS, NATURAL; LEUKAPHERESIS; MALE;

EID: 84946841813     PISSN: 17232007     EISSN: 23852070     Source Type: Journal    
DOI: 10.2450/2015.0231-14     Document Type: Article

References (29)

1. Robertson MJ, Ritz J. Biology and clinical relevance of human natural killer cells. Blood 1990; 76: 2421-38.
2. Miller JS. The biology of natural killer cells in cancer, infection, and pregnancy. Exp Hematol 2001; 29: 1157-68.
3. Thielens A, Vivier E, Romagné F. NK cell MHC class I specific receptors (KIR): from biology to clinical intervention. Curr Opin Immunol 2012; 24: 239-45.
4. Moretta A, Bottino C, Vitale M, et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 2001; 19: 197-223.
5. Coudert JD, Held W. The role of the NKG2D receptor for tumor immunity. Semin Cancer Biol 2006; 16: 333-43.
6. Eagle RA, Trowsdale J. Promiscuity and the single receptor: NKG2D. Nat Rev Immunol 2007; 7: 737-44.
7. Shibuya A, Campbell D, Hannum C, et al. DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes. Immunity 1996; 4: 573-81.
8. Carlens S, Gilljam M, Chambers BJ, et al. A new method for in vitro expansion of cytotoxic human CD3-CD56+ natural killer cells. Hum Immunol 2001; 62: 1092-8.
9. McKenna DH, Jr, Sumstad D, Bostrom N, et al. Good manufacturing practices production of natural killer cells for immunotherapy: a six-year single-institution experience. Transfusion 2007; 47: 520-8.
10. Torelli GF, Guarini A, Maggio R, et al. Expansion of natural killer cells with lytic activity against autologous blasts from adult and pediatric acute lymphoid leukemia patients in complete hematologic remission. Haematologica 2005; 90: 785-92.
11. Luhm J, Brand JM, Koritke P, et al. Large-scale generation of natural killer lymphocytes for clinical application. J Hematother Stem Cell Res 2002; 11: 651-7.
12. Fujisaki H, Kakuda H, Shimasaki N, et al. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res 2009; 69: 4010-7.
13. Perussia B, Ramoni C, Anegon I, et al. Preferential proliferation of natural killer cells among peripheral blood mononuclear cells cocultured with B lymphoblastoid cell lines. Nat Immun Cell Growth Regul 1987; 6: 171-88.
14. Miller JS, Oelkers S, Verfaillie C, McGlave P. Role of monocytes in the expansion of human activated natural killer cells. Blood 1992; 80: 2221-9.
15. Boissel L, Tuncer HH, Betancur M, et al. Umbilical cord mesenchymal stem cells increase expansion of cord blood natural killer cells. Biol Blood Marrow Transplant 2008; 14: 1031-8.
16. Suck G, Koh MB. Emerging natural killer cell immunotherapies: large-scale ex vivo production of highly potent anticancer effectors. Hematol Oncol Stem Cell Ther 2010; 3: 135-42.
17. Miller JS. Should natural killer cells be expanded in vivo or ex vivo to maximize their therapeutic potential? Cytotherapy 2009; 11: 259-60.
18. Ahn YO, Kim S, Kim TM, et al. Irradiated and activated autologous PBMCs induce expansion of highly cytotoxic human NK cells in vitro. J Immunother 2013; 36: 373-81.
19. Siegler U, Meyer-Monard S, Jörger S, et al. Good manufacturing practice-compliant cell sorting and large-scale expansion of single KIR-positive alloreactive human natural killer cells for multiple infusions to leukemia patients. Cytotherapy 2010; 12: 750-63.
20. Cramer P, Hallek M. Hematological cancer in 2011: new therapeutic targets and treatment strategies. Nat Rev Clin Oncol 2012; 9: 72-4.
21. Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005; 105: 3051-7.
22. Knorr DA, Bachanova V, Verneris MR, Miller JS. Clinical utility of natural killer cells in cancer therapy and transplantation. Semin Immunol 2014; 26: 161-72.
23. Peragine N, Torelli GF, Mariglia P, et al. Immunophenotypic and functional characterization of ex vivo expanded natural killer cells for clinical use in acute lymphoblastic leukemia patients. Cancer Immunol Immunother 2015; 64: 201-11.
24. Torelli GF, Peragine N, Raponi S, et al. Recognition of adult and pediatric acute lymphoblastic leukemia blasts by natural killer cells. Haematologica 2014; 99: 1248-54.
25. Bachanova V, Burns LJ, McKenna DH, et al. Allogeneic natural killer cells for refractory lymphoma. Cancer Immunol Immunother 2010; 59: 1739-44.
26. Rubnitz JE, Inaba H, Ribeiro RC, et al. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol 2010; 28: 955-9.
27. Curti A, Ruggeri L, D'Addio A, et al. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. Blood 2011; 118: 3273-9.
28. Liao W, Lin J-X, Leonard WJ. Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity 2013; 38: 13-25.
29. Croce M, Orengo AM, Azzarone B, Ferrini S. Immunotherapeutic applications of IL-15. Immunotherapy 2012; 4: 957-69.